Has pharmacogenetics brought us closer to 'personalized medicine' for initial drug treatment of hypertension?

Current Opinion in Cardiology

Volumn 24, Issue 4, 2009, Pages 333-339

  Arnett, Donna K ^a   Claas, Steven A ^a   Lynch, Amy I ^b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Antihypertensive pharmacogenetics; Genes; Hypertension; Personalized medicine

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; FOSINOPRIL; IRBESARTAN; LISINOPRIL; PERINDOPRIL; RENIN ANGIOTENSIN SYSTEM BLOCKER; RENIN INHIBITOR; UNCLASSIFIED DRUG; VERAPAMIL;

ADRENERGIC SYSTEM; BLOOD VESSEL TONE; CLINICAL TRIAL; FLUID BALANCE; GENETIC VARIABILITY; HUMAN; HYPERTENSION; ION TRANSPORT; LEGAL ASPECT; PHARMACOGENETICS; PHYSICIAN; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SOCIAL ASPECT; TREATMENT OUTCOME; DRUG DESIGN; DRUG EFFECTS; EVIDENCE BASED MEDICINE; GENETICS; GENOTYPE; TIME;

ANTIHYPERTENSIVE AGENTS; DRUG DESIGN; EVIDENCE-BASED MEDICINE; GENOTYPE; HUMANS; HYPERTENSION; PHARMACOGENETICS; RENIN-ANGIOTENSIN SYSTEM; TIME FACTORS;

EID: 67651165181     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/HCO.0b013e32832c58ba     Document Type: Review

References (33)

1. Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and stroke statistics: 2009 update. A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008; 119:e1-e161.
2. Kearney PM, Whelton M, Reynolds K, et al. Worldwide prevalence of hypertension: a systematic review. J Hypertens 2004; 22:11-19. (Pubitemid 38293521)
3. Filigheddu F, Argiolas G, Bulla E, et al. Clinical variables, not RAAS polymorphisms, predict blood pressure response to ACE inhibitors in Sardinians. Pharmacogenomics 2008; 9:1419-1427.
4. Gluszek J, Jankowska K. Is there relationship between the A1166C polymorphism of the angiotensin II receptor AT1 and plasma renin activity, insulin resistance and reduction of blood pressure after angiotensin-converting enzyme inhibitor therapy? Pol Arch Med Wewn 2008; 118:194-200.
5. Kelley-Hedgepeth A, Peter I, Kip K, et al. The protective effect of KCNMB1 E65K against hypertension is restricted to blood pressure treatment with beta-blockade. J Hum Hypertens 2008; 22:512-515. (Pubitemid 351877740)
6. Kurland L, Hallberg P, Melhus H, et al. The relationship between the plasma concentration of irbesartan and the antihypertensive response is disclosed by an angiotensin II type 1 receptor polymorphism: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs. Atenolol (SILVHIA) Trial. Am J Hypertens 2008; 21:836-839. (Pubitemid 351913624)
7. Lemaitre RN, Heckbert SR, Sotoodehnia N, et al. Beta1- and beta2-adrenergic receptor gene variation, beta-blocker use and risk of myocardial infarction and stroke. Am J Hypertens 2008; 21:290-296. (Pubitemid 351323282)
8. Lynch AI, Boerwinkle E, Davis BR, et al. Pharmacogenetic association of the NPPA T2238C genetic variant with cardiovascular disease outcomes in patients with hypertension. JAMA 2008; 299:296-307. This research using data from the largest pharmacogenetic study to date showed a pharmacogenetic effect of an NPPA variant on multiple outcomes. The consistency of the association with multiple clinical outcomes and BP change lends credibility to the findings. (Pubitemid 351159366)
9. Manunta P, Lavery G, Lanzani C, et al. Physiological interaction between alpha-adducin and WNK1-NEDD4L pathways on sodium-related blood pressure regulation. Hypertension 2008; 52:366-372. This study employed a method for assessing associations between treatment and variants from multiple genes with BP response.
10. Pacanowski M, Gong Y, Cooper-Dehoff R, et al. Beta-adrenergic receptor gene polymorphisms and beta-blocker treatment outcomes in hypertension. Clin Pharmacol Ther 2008; 84:715-721.
11. Schelleman H, Klungel OH, Witteman JC, et al. Interaction between polymorphisms in the renin-angiotensin-system and angiotensin-converting enzyme inhibitor or beta-blocker use and the risk of myocardial infarction and stroke. Pharmacogenomics J 2008; 400-407.
12. Turner ST, Bailey KR, Fridley BL, et al. Genomic association analysis suggests chromosome 12 locus influencing antihypertensive response to thiazide diuretic. Hypertension 2008; 52:359-365. This study illustrates the potential that the GWAS methodology has for identifying novel genes that may play a role in the response to antihypertensive drug treatment. Such studies may not only prove valuable in the move toward clinical pharmacogenetics, but may also advance our biological understanding of hypertension and its treatment.
13. Arnett DK, Davis BR, Ford CE, et al. Pharmacogenetic association of the angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: the Genetics of Hypertension-Associated Treatment (GenHAT) study. Circulation 2005; 111:3374-3383.
14. Stavroulakis GA, Makris TK, Krespi PG, et al. Predicting response to chronic antihypertensive treatment with fosinopril: the role of angiotensin-converting enzyme gene polymorphism. Cardiovasc Drugs Ther 2000; 14:427-432.
15. Hingorani AD, Jia H, Stevens PA, et al. Renin-angiotensin system gene polymorphisms influence blood pressure and the response to angiotensin converting enzyme inhibition. J Hypertens 1995; 13:1602-1609. (Pubitemid 26015783)
16. Miller JA, Thai K, Scholey JW. Angiotensin II type 1 receptor gene polymorphism predicts response to losartan and angiotensin II. Kidney Int 1999; 56:2173-2180. (Pubitemid 30004746)
17. Liu J, Liu ZQ, Yu BN, et al. Beta1-adrenergic receptor polymorphisms influence the response to metoprolol monotherapy in patients with essential hypertension. Clin Pharmacol Ther 2006; 80:23-32. (Pubitemid 43946840)
18. Johnson JA, Zineh I, Puckett BJ, et al. Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol. Clin Pharmacol Ther 2003; 74:44-52. (Pubitemid 36776175)
19. Hindorff LA, Heckbert SR, Psaty BM, et al. beta(2)-adrenergic receptor polymorphisms and determinants of cardiovascular risk: the Cardiovascular Health Study. Am J Hypertens 2005; 18:392-397.
20. Liu J, Liu ZQ, Tan ZR, et al. Gly389Arg polymorphism of beta1-adrenergic receptor is associated with the cardiovascular response to metoprolol. Clin Pharmacol Ther 2003; 74:372-379. (Pubitemid 37222858)
21. Karlsson J, Lind L, Hallberg P, et al. Beta1-adrenergic receptor gene polymorphisms and response to beta1-adrenergic receptor blockade in patients with essential hypertension. Clin Cardiol 2004; 27:347-350. (Pubitemid 38703089)
22. Dishy V, Sofowora GG, Xie HG, et al. The effect of common polymorphisms of the beta2-adrenergic receptor on agonist-mediated vascular desensitization. N Engl J Med 2001; 345:1030-1035. (Pubitemid 34940795)
23. Glorioso N, Manunta P, Filigheddu F, et al. The role of alpha-adducin polymorphism in blood pressure and sodium handling regulation may not be excluded by a negative association study. Hypertension 1999; 34:649-654. (Pubitemid 29496448)
24. Rodwell GE, Sonu R, Zahn JM, et al. A transcriptional profile of aging in the human kidney. PLoS Biol 2004; 2:e427. (Pubitemid 40280523)
25. Xiao R, Boehnke M. Quantifying and correcting for the winner's curse in genetic association studies. Genet Epidemiol 2009. [Epub ahead of print]
26. de Leon J, Arranz MJ, Ruano G. Pharmacogenetic testing in psychiatry: a review of features and clinical realities. Clin Lab Med 2008; 28:599-617.
27. Klein TE, Altman RB, Eriksson N, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009; 360:753-764.
28. Flockhart DA, O'Kane D, Williams MS, et al. Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. Genet Med 2008; 10:139-150. (Pubitemid 351271726)
29. Burke S, Stone A, Bedward J, et al. A 'neglected part of the curriculum' or 'of limited use'? Views on genetics training by nongenetics medical trainees and implications for delivery. Genet Med 2006; 8:109-115.
30. Fargher EA, Eddy C, Newman W, et al. Patients' and healthcare professionals' views on pharmacogenetic testing and its future delivery in the NHS. Pharmacogenomics 2007; 8:1511-1519. (Pubitemid 350286396)
31. Rogausch A, Prause D, Schallenberg A, et al. Patients' and physicians' perspectives on pharmacogenetic testing. Pharmacogenomics 2006; 7:49-59.
32. Khoury MJ, Berg A, Coates R, et al. The evidence dilemma in genomic medicine. Health Aff (Millwood) 2008; 27:1600-1611.
33. Khoury MJ, Gwinn M, Yoon PW, et al. The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into healthcare and disease prevention? Genet Med 2007; 9:665-674.